All Stories

  1. Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma

    Article • American Journal of Clinical Oncology, January 2019, Wolters Kluwer Health

    GAETANO FACCHINI

  2. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

    Article • Journal of Global Oncology, November 2018, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  3. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

    Article • Immunotherapy, October 2018, Future Medicine

    Melissa Bersanelli, GAETANO FACCHINI, Dr Sebastiano Buti

  4. Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases

    Article • Anti-Cancer Drugs, October 2018, Wolters Kluwer Health

    GAETANO FACCHINI

  5. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

    Article • Clinical Genitourinary Cancer, October 2018, Elsevier

    GAETANO FACCHINI, Dr Sebastiano Buti

  6. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program

    Article • Future Oncology, September 2018, Future Medicine

    GAETANO FACCHINI

  7. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

    Article • Anti-Cancer Drugs, August 2018, Wolters Kluwer Health

    GAETANO FACCHINI, Dr Sebastiano Buti

  8. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

    Article • Clinical Genitourinary Cancer, August 2018, Elsevier

    GAETANO FACCHINI, Dr Sebastiano Buti

  9. Processed Meat and Risk of Renal Cell and Bladder Cancers

    Article • Nutrition and Cancer, March 2018, Taylor & Francis

    Pagona Lagiou, GAETANO FACCHINI

  10. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study

    Article • Oncotarget, March 2018, Impact Journals, LLC

    GAETANO FACCHINI

  11. Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies

    Article • Oncotarget, March 2018, Impact Journals, LLC

    GAETANO FACCHINI

  12. Microbiota effects on cancer: from risks to therapies

    Article • Oncotarget, March 2018, Impact Journals, LLC

    GAETANO FACCHINI

  13. Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study.

    Article • Journal of Clinical Oncology, February 2018, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  14. Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).

    Article • Journal of Clinical Oncology, February 2018, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  15. Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.

    Article • Journal of Clinical Oncology, February 2018, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  16. Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer

    Article • Current Molecular Medicine, February 2018, Bentham Science Publishers

    GAETANO FACCHINI

  17. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

    Article • The Lancet Oncology, February 2018, Elsevier

    GAETANO FACCHINI

  18. Proanthocyanidins and the risk of prostate cancer in Italy

    Article • Cancer Causes & Control, January 2018, Springer Science + Business Media

    GAETANO FACCHINI

  19. Primitive Mediastinal Germ Cell Tumors: An Update

    Article • January 2018, Springer Science + Business Media

    GAETANO FACCHINI

  20. Ipilimumab for the treatment of metastatic prostate cancer

    Article • Expert Opinion on Biological Therapy, December 2017, Taylor & Francis

    GAETANO FACCHINI

  21. Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment

    Article • The Neuroradiology Journal, December 2017, SAGE Publications

    GAETANO FACCHINI

  22. Exploring the molecular aspects associated with testicular germ cell tumors: a review

    Article • Oncotarget, November 2017, Impact Journals, LLC

    GAETANO FACCHINI

  23. Coffee Decreases the Risk of Endometrial Cancer: A Dose–Response Meta-Analysis of Prospective Cohort Studies

    Article • Nutrients, November 2017, MDPI AG

    GAETANO FACCHINI

  24. Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results

    Article • Frontiers in Pharmacology, November 2017, Frontiers

    GAETANO FACCHINI

  25. Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a case–control study

    Article • British Journal Of Nutrition, October 2017, Cambridge University Press

    GAETANO FACCHINI

  26. Testicular cancer from diagnosis to epigenetic factors

    Article • Oncotarget, September 2017, Impact Journals, LLC

    GAETANO FACCHINI

  27. Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences

    Article • Oncotarget, September 2017, Impact Journals, LLC

    GAETANO FACCHINI

  28. First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

    Article • Clinical Genitourinary Cancer, August 2017, Elsevier

    GAETANO FACCHINI, Melissa Bersanelli, Dr Sebastiano Buti

  29. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

    Article • New England Journal of Medicine, July 2017, New England Journal of Medicine (NEJM/MMS)

    GAETANO FACCHINI

  30. Micrornas in prostate cancer: an overview

    Article • Oncotarget, July 2017, Impact Journals, LLC

    GAETANO FACCHINI

  31. Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma

    Article • Frontiers in Pharmacology, July 2017, Frontiers

    GAETANO FACCHINI

  32. A rare case of malignant solitary fibrous tumor in prostate with review of the literature

    Article • Diagnostic Pathology, July 2017, Springer Science + Business Media

    GAETANO FACCHINI

  33. Family history of cancer and the risk of bladder cancer: A case–control study from Italy

    Article • Cancer Epidemiology, June 2017, Elsevier

    GAETANO FACCHINI

  34. PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

    Article • Medicine, June 2017, Wolters Kluwer Health

    GAETANO FACCHINI

  35. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone

    Article • The Prostate, April 2017, Wiley

    GAETANO FACCHINI

  36. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

    Article • European Urology Focus, April 2017, Elsevier

    GAETANO FACCHINI

  37. Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis

    Article • Oncotarget, March 2017, Impact Journals, LLC

    GAETANO FACCHINI, MD Vincenzo Ravo

  38. Serum and tissue markers in colorectal cancer: State of art

    Article • Critical Reviews in Oncology/Hematology, March 2017, Elsevier

    GAETANO FACCHINI

  39. Vinflunine and bladder cancer: present and future indications

    Article • February 2017, PAGEPress Publications

    GAETANO FACCHINI

  40. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications

    Article • Oncotarget, February 2017, Impact Journals, LLC

    GAETANO FACCHINI

  41. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma

    Article • Current Cancer Drug Targets, February 2017, Bentham Science Publishers

    GAETANO FACCHINI

  42. Optimal Management of Prostate Cancer Based on its Natural Clinical History

    Article • Current Cancer Drug Targets, February 2017, Bentham Science Publishers

    GAETANO FACCHINI

  43. The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers: Clinical Impact and Cost Consideration.

    Article • Current Cancer Drug Targets, February 2017, Bentham Science Publishers

    GAETANO FACCHINI

  44. MELANOMA ADJUVANT TREATMENT: current insight and clinical features

    Article • Current Cancer Drug Targets, February 2017, Bentham Science Publishers

    GAETANO FACCHINI

  45. Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients

    Article • Anti-Cancer Drugs, January 2017, Wolters Kluwer Health

    GAETANO FACCHINI

  46. ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review

    Article • International Journal of Medical Sciences, January 2017, Ivyspring International Publisher

    GAETANO FACCHINI

  47. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin

    Article • Gynecologic Oncology, January 2017, Elsevier

    GAETANO FACCHINI

  48. Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey

    Article • Oncotarget, December 2016, Impact Journals, LLC

    GAETANO FACCHINI

  49. Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

    Article • Frontiers in Pharmacology, December 2016, Frontiers

    GAETANO FACCHINI

  50. Tumour biomarkers: homeostasis as a novel prognostic indicator

    Article • Open Biology, December 2016, Royal Society Publishing

    GAETANO FACCHINI

  51. New treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy

    Article • Expert Opinion on Pharmacotherapy, November 2016, Taylor & Francis

    GAETANO FACCHINI

  52. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma

    Article • Frontiers in Pharmacology, November 2016, Frontiers

    GAETANO FACCHINI

  53. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review

    Article • Oncotarget, November 2016, Impact Journals, LLC

    GAETANO FACCHINI

  54. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

    Article • Cancer Biology & Therapy, October 2016, Taylor & Francis

    GAETANO FACCHINI, VALERIO NARDONE

  55. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone

    Article • Frontiers in Pharmacology, October 2016, Frontiers

    GAETANO FACCHINI

  56. Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study

    Article • Frontiers in Pharmacology, September 2016, Frontiers

    MICHELE DE TURSI, GAETANO FACCHINI

  57. Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

    Article • Frontiers in Pharmacology, August 2016, Frontiers

    GAETANO FACCHINI

  58. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review

    Article • Expert Opinion on Biological Therapy, August 2016, Taylor & Francis

    GAETANO FACCHINI

  59. Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review)

    Article • Oncology Reports, June 2016, Spandidos Publications

    GAETANO FACCHINI

  60. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study

    Article • Oncotarget, May 2016, Impact Journals, LLC

    GAETANO FACCHINI

  61. Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

    Article • Frontiers in Pharmacology, May 2016, Frontiers

    GAETANO FACCHINI

  62. From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples

    Article • Frontiers in Pharmacology, May 2016, Frontiers

    GAETANO FACCHINI

  63. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

    Article • Future Oncology, February 2016, Future Medicine

    Giovanni Lo Re, GAETANO FACCHINI

  64. Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival.

    Article • Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  65. Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.

    Article • Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  66. Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminar...

    Article • Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI, Giovanni Lo Re

  67. Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.

    Article • Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  68. Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX

    Article • BioMed Research International, January 2016, Hindawi Publishing Corporation

    GAETANO FACCHINI

  69. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer

    Article • Future Oncology, November 2015, Future Medicine

    GAETANO FACCHINI

  70. Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer

    Article • Oncology, October 2015, Karger Publishers

    GAETANO FACCHINI

  71. F21When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting

    Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

    GAETANO FACCHINI

  72. 2549 Treatment patterns in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis

    Article • European Journal of Cancer, September 2015, Elsevier

    GAETANO FACCHINI

  73. Epithelial-mesenchymal transition in prostate cancer: an overview

    Article • Oncotarget, July 2015, Impact Journals, LLC

    GAETANO FACCHINI

  74. Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences

    Article • Oncotarget, July 2015, Impact Journals, LLC

    GAETANO FACCHINI

  75. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

    Article • European Urology, July 2015, Elsevier

    GAETANO FACCHINI, Giovanni Lo Re

  76. Gene interference strategies as a new tool for the treatment of prostate cancer

    Article • Endocrine, June 2015, Springer Science + Business Media

    GAETANO FACCHINI

  77. Corrigendum

    Article • Future Oncology, June 2015, Future Medicine

    Dr Sebastiano Buti, GAETANO FACCHINI, Giovanni Lo Re

  78. Endocrine disruptors and female cancer: Informing the patients (Review)

    Article • Oncology Reports, May 2015, Spandidos Publications

    GAETANO FACCHINI

  79. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

    Article • Future Oncology, March 2015, Future Medicine

    GAETANO FACCHINI, Dr Sebastiano Buti, Giovanni Lo Re

  80. The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer

    Article • Anti-Cancer Drugs, February 2015, Wolters Kluwer Health

    GAETANO FACCHINI

  81. Ovarian cancer standard of care: are there real alternatives?

    Article • Chinese Journal of Cancer, January 2015, Editorial Office of Chinese Journal of Cancer

    GAETANO FACCHINI

  82. Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study

    Article • Future Oncology, January 2015, Future Medicine

    GAETANO FACCHINI

  83. P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentr...

    Article • European Urology Supplements, November 2014, Elsevier

    GAETANO FACCHINI

  84. Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk

    Article • Anti-Cancer Drugs, August 2014, Wolters Kluwer Health

    GAETANO FACCHINI

  85. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion

    Article • Journal of Experimental & Clinical Cancer Research, January 2014, Springer Science + Business Media

    GAETANO FACCHINI

  86. Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)

    Article • Oncology, January 2014, Karger Publishers

    GAETANO FACCHINI

  87. Current strategies to minimize toxicity of oxaliplatin

    Article • Anti-Cancer Drugs, November 2013, Wolters Kluwer Health

    GAETANO FACCHINI

  88. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment

    Article • Anti-Cancer Drugs, November 2013, Wolters Kluwer Health

    GAETANO FACCHINI

  89. Interleukin-2 and Lanreotide in the Treatment of Medullary Thyroid Cancer: In Vitro and In Vivo Studies

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2013, Endocrine Society

    GAETANO FACCHINI

  90. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study

    Article • Journal of Translational Medicine, July 2013, Springer Science + Business Media

    GAETANO FACCHINI

  91. Multidisciplinary Treatment of Early Stage Endometrial Cancer

    Article • Anti-Cancer Agents in Medicinal Chemistry, June 2013, Bentham Science Publishers

    GAETANO FACCHINI

  92. Testicular and testicular adnexa tumors in the elderly

    Article • Anti-Cancer Drugs, March 2013, Wolters Kluwer Health

    GAETANO FACCHINI

  93. Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI, Giovanni Lo Re

  94. Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression

    Article • Current Medicinal Chemistry, February 2013, Bentham Science Publishers

    GAETANO FACCHINI

  95. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients

    Article • Anti-Cancer Drugs, February 2013, Wolters Kluwer Health

    GAETANO FACCHINI

  96. Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression

    Article • Current Medicinal Chemistry, February 2013, Bentham Science Publishers

    GAETANO FACCHINI

  97. Neuroendocrine Differentiation in Prostate Cancer

    Article • January 2013, Springer Science + Business Media

    Ph.D Paolo Chieffi, GAETANO FACCHINI

  98. Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

    Article • Journal of Drug Delivery, January 2013, Hindawi Publishing Corporation

    GAETANO FACCHINI

  99. Urotensin-II Receptor Regulates Cell Mobility/Invasion and Determines Prognosis of Bladder Cancer

    Article • January 2013, Prompt Scientific Publishing

    GAETANO FACCHINI

  100. P118 Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)

    Article • European Urology Supplements, November 2012, Elsevier

    GAETANO FACCHINI

  101. High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer

    Article • Current Cancer Drug Targets, May 2012, Bentham Science Publishers

    GAETANO FACCHINI

  102. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up

    Article • Annals of Oncology, December 2011, Oxford University Press (OUP)

    GAETANO FACCHINI

  103. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms

    Article • Oncology Reports, October 2011, Spandidos Publications

    GAETANO FACCHINI

  104. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era

    Article • Journal of Neuro-Oncology, October 2011, Springer Science + Business Media

    GAETANO FACCHINI, Giovanni Lo Re

  105. 7059 POSTER Incidence and Outcomes of Brain and Meningeal Metastases (BMm) in Patients With Castration-resistant Prostate Cancer (CRPC) in the Era of Docetaxel (DOC)

    Article • European Journal of Cancer, September 2011, Elsevier

    GAETANO FACCHINI, Giovanni Lo Re

  106. The role of tissue microarray in the era of target-based agents

    Article • Expert Review of Anticancer Therapy, June 2011, Taylor & Francis

    GAETANO FACCHINI

  107. Expression of lumbosacral HOX genes, crucial in kidney organogenesis, is systematically deregulated in clear cell kidney cancers

    Article • Anti-Cancer Drugs, June 2011, Wolters Kluwer Health

    Dr alfredo procino, Luca Cindolo, GAETANO FACCHINI

  108. Chemotherapy in epithelial ovarian cancer

    Article • Cancer Letters, April 2011, Elsevier

    GAETANO FACCHINI

  109. Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients

    Article • Clinical Journal of Pain, January 2011, Wolters Kluwer Health

    GAETANO FACCHINI

  110. Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

    Article • Current Cancer Drug Targets, November 2010, Bentham Science Publishers

    GAETANO FACCHINI

  111. Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial

    Article • Cancer Biology & Therapy, September 2010, Taylor & Francis

    GAETANO FACCHINI

  112. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials

    Article • Cancer Chemotherapy and Pharmacology, March 2010, Springer Science + Business Media

    GAETANO FACCHINI

  113. First-line treatment of advanced ovarian cancer: current research and perspectives

    Article • Expert Review of Anticancer Therapy, January 2010, Taylor & Francis

    GAETANO FACCHINI

  114. New treatment approaches in renal cell carcinoma

    Article • Anti-Cancer Drugs, November 2009, Wolters Kluwer Health

    GAETANO FACCHINI

  115. Effects of Transdermal Buprenorphine on Patients-reported Outcomes in Cancer Patients

    Article • Clinical Journal of Pain, October 2009, Wolters Kluwer Health

    GAETANO FACCHINI

  116. Target-based agents in neo-adjuvant treatment of liver metastases from colo-rectal cancer: Secret weapons in anticancer war?

    Article • Cancer Biology & Therapy, September 2009, Taylor & Francis

    GAETANO FACCHINI

  117. 1245 Zoledronic acid and Taxotere (ZANTE) metronomic and sequential administration in patients with hormone refractory prostate cancer (HRPC) – final results of phase I study

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    GAETANO FACCHINI

  118. Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways

    Article • Current Cancer Drug Targets, August 2009, Bentham Science Publishers

    GAETANO FACCHINI

  119. Treatment of recurrent epithelial ovarian cancer

    Article • Therapeutics and Clinical Risk Management, June 2009, Taylor & Francis

    GAETANO FACCHINI

  120. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group

    Article • British Journal of Cancer, April 2009, Springer Science + Business Media

    GAETANO FACCHINI

  121. Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    GAETANO FACCHINI

  122. Sunitinib in advanced clear cell renal cancer: A single centre experience

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    GAETANO FACCHINI

  123. Tamoxifen in the treatment of recurrent, advanced border line ovarian cancer: A single centre experience

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    GAETANO FACCHINI

  124. Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    GAETANO FACCHINI

  125. Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan

    Article • Annals of Oncology, August 2007, Oxford University Press (OUP)

    Ph. D, MIAC Franco Fulciniti, GAETANO FACCHINI

  126. Concomitant Occurrence of Facial Cutaneous and Parotid Gland Metastases from Rectal Cancer after Preoperative Chemoradiotherapy

    Article • Oncology Research and Treatment, May 2007, Karger Publishers

    GAETANO FACCHINI

  127. Phase II studies of anticancer chemotherapy: indirect evidence of poor quality

    Article • Annals of Oncology, November 2006, Oxford University Press (OUP)

    GAETANO FACCHINI

  128. Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients

    Article • Clinical Cancer Research, May 2006, American Association for Cancer Research (AACR)

    GAETANO FACCHINI

  129. A prospective comparison of polyflex and ultraflex stents for palliation of inoperable malignant esophageal strictures. Preliminary report

    Article • Digestive and Liver Disease, April 2006, Elsevier

    GAETANO FACCHINI

  130. Stop Flow in abdominal and pelvic cancer relapses

    Article • Frontiers in Bioscience, January 2006, Frontiers in Bioscience

    GAETANO FACCHINI

  131. A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications

    Article • Annals of Oncology, July 2005, Oxford University Press (OUP)

    GAETANO FACCHINI

  132. Gastric cancer. treatment of advanced disease and new drugs

    Article • Frontiers in Bioscience, January 2005, Frontiers in Bioscience

    GAETANO FACCHINI

  133. Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells

    Article • Frontiers in Bioscience, January 2005, Frontiers in Bioscience

    GAETANO FACCHINI

  134. Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers

    Article • European Journal of Surgical Oncology, August 2004, Elsevier

    GAETANO FACCHINI

  135. Percutaneous Ethanol Injection Efficacy in the Treatment of Large Symptomatic Thyroid Cystic Nodules: Ten-Year Follow-Up of a Large Series

    Article • Thyroid, September 2002, Mary Ann Liebert Inc

    GAETANO FACCHINI

  136. Phase I–II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB–IV non-small cell lung cancer

    Article • Lung Cancer, December 2000, Elsevier

    GAETANO FACCHINI

  137. Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer

    Article • Journal of Clinical Oncology, March 1999, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI

  138. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer

    Article • Breast Cancer Research and Treatment, January 1998, Springer Science + Business Media

    GAETANO FACCHINI

  139. Phase I study of vinorelbine and paclitaxel in small-cell lung cancer

    Article • Cancer Chemotherapy and Pharmacology, November 1997, Springer Science + Business Media

    GAETANO FACCHINI

  140. Abdominal and pelvic stop-flow (hypoxic, chemotherapeutic loco-regional treatment): Preliminary report of a phase I study

    Article • European Journal of Cancer, September 1997, Elsevier

    GAETANO FACCHINI

  141. Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer

    Article • European Journal of Cancer, October 1996, Elsevier

    GAETANO FACCHINI, MD Vincenzo Ravo

  142. A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

    Article • British Journal of Cancer, November 1995, Springer Science + Business Media

    GAETANO FACCHINI

  143. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer

    Article • Breast Cancer Research and Treatment, September 1995, Springer Science + Business Media

    GAETANO FACCHINI

  144. NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC-CANCER - PRELIMINARY-RESULTS OF A PHASE-II TRIAL WITH A MODIFIED FAMTX COMBINATION

    Article • Oncology Reports, September 1995, Spandidos Publications

    GAETANO FACCHINI

  145. A PHASE-II TRIAL OF 5-FLUOROURACIL, FOLINIC ACID, VINORELBINE IN PRETREATED PATIENTS WITH METASTIC COLORECTAL-CANCER

    Article • Oncology Reports, July 1995, Spandidos Publications

    GAETANO FACCHINI

  146. Chlorambucil, Vincristine and Cytarabine (COA) Treatment of Low Grade Lymphomas

    Article • Leukemia & Lymphoma, January 1995, Taylor & Francis

    GAETANO FACCHINI

  147. RECOVERY OF SENSITIVITY TO CISPLATINUM AND EPIDOXORUBICIN BY IONIDAMINE AND INTERFERON IN ADVANCED OVARIAN-CANCER

    Article • International Journal of Oncology, June 1994, Spandidos Publications

    GAETANO FACCHINI

  148. PREOPERATIVE CHEMOIMMUNOTHERAPY WITH CARBOPLATIN, EPIDOXORUBICIN, 5-FLUOROURACIL AND ALPHA-2B INTERFERON IN LOCALLY ADVANCED INOPERABLE GASTRIC-CANCER

    Article • International Journal of Oncology, June 1994, Spandidos Publications

    GAETANO FACCHINI

  149. HYPERFRACTIONATED SPLIT-COURSE THORACIC RADIATION-THERAPY PLUS CHEMOTHERAPY IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER

    Article • International Journal of Oncology, March 1994, Spandidos Publications

    GAETANO FACCHINI

  150. Inflammatory breast cancer: Combined therapy with chemotherapy plus lonidamine, surgery and radiotherapy

    Article • European Journal of Cancer, January 1994, Elsevier

    GAETANO FACCHINI

  151. Carboplatin and α-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study

    Article • European Journal of Cancer, January 1994, Elsevier

    GAETANO FACCHINI

  152. Intraperitoneal (ip) Cisplatin-Mitoxantrone-Interferon-α2b in Ovarian Cancer Patients with Minimal Residual Disease

    Article • Gynecologic Oncology, July 1993, Elsevier

    GAETANO FACCHINI

  153. Effect of hyperthermia combined with radiation on refractory tumors. Preliminary data

    Article • European Journal of Cancer, January 1993, Elsevier

    GAETANO FACCHINI

  154. Lonidamine, alpha 2B interferon and high-dose epirubicin in advanced breast cancer

    Article • European Journal of Cancer, January 1993, Elsevier

    GAETANO FACCHINI

  155. Navelbine plus 5-FU and folinic acid (FA) in pretreated colo-rectal cancer patients. Preliminary data

    Article • European Journal of Cancer, January 1993, Elsevier

    GAETANO FACCHINI

  156. Salvage chemotherapy (CT) with combination of carboplatin (CBDCA) and vinorelbine (VRB) in advanced breast cancer (ABC)

    Article • European Journal of Cancer, January 1993, Elsevier

    GAETANO FACCHINI